New data in MDS. Onconova presented data at the American Society of Hematology (ASH) annual meeting in December. The data update included genomic profiling from INSPIRE study patients, who suffer from higher risk myelodysplastic syndrome (HR-MDS). We don't expect any value generating data until topline readout from INSPIRE study in 2020. In this report, we have highlighted recent data readouts in MDS landscape. What's new in MDS and what it means for rigosertib. Forty Seven (FTSV, Not covered)'s magrolimab and Abbvie (ABBV, Not covered)'s venetoclax made the most impact in HR-MDS field. Onconova's rigosertib has shown similar ORR to magrolimab (92%), but superior ORR to venetoclax (90% versus 70%). Magrolimab showed the highest CR rates with...Read More >>